main content start

Homepage

Latest Videos

Latest Videos

Breast Cancer

Breast Cancer

Brightcove Cards Listing

Prostate Cancer

Multiple Myeloma

Multiple Myeloma

Brightcove Cards Listing

Popular on MedEnrich

Popular in No name
  • Myelodysplastic Syndromes14m 13s

    ASH 2022 Update on Myelodysplastic Syndromes

    ASH 2022 - Update on Myelodysplastic Syndromes
    low risk mds eln classification low dose lenalidomide viale -a tags: azacitidine venetoclax
  • Prostate Cancer45m 55s

    Treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC)

    Treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC)
    metastatic hormone-sensitive prostate cancer (mhspc) androgen deprivation therapy (adt) chemotherapy docetaxel improved patient survival rates
  • Breast Cancer3m 56s

    Duration of trastuzumab in patients with Her2 positive Metastatic Breast Cancer in prolonged remission

    There are no randomized clinical trials addressing the continued use of Trastuzumab for Her2 positive MBC patients in prolonged remission and has become important and relevant clinical question.
    her2 positive mbc prolonged remission trastuzumab duration
  • Myelodysplastic Syndromes7m 3s

    Clinical Application of Web Based Tool for Improving MDS Diagnosis

    Gradient Based Model based on 10 routinely used parameters (Age, Gender, Hb, WBC, MCV, Platelets, Neutrophils, Monocytes, Glucose, Creatinine) is now available to facilitate non-invasive diagnosis of MDS.
    mds non-invasive diagnosis
  • Breast Cancer8m 50s

    Immunotherapy of Early Breast Cancer

    I-SPY2 clinical trial laid the foundation for Immunotherapy in Early Breast Cancer with Pembrolizumab added to Neoadjuvant Chemotherapy.
    keynote -522 immunotherapy early breast cancer
  • Oncology9m 34s

    Case Based Learning in Cardio Oncology

    Immunotherapy mediated cardiotoxicity like myocarditis & cardiovascular issues arising of cytokine release syndrome can become more common with increasing adoption of Immunotherapy in cancer treatment.
    car-t cell therapy cytokine release syndrome immunotherapy mediated myocarditis
  • Breast Cancer14m 46s

    ESMO 2022 Breast Cancer Comprehensive Coverage

    View comprehensive coverage of Breast Cancer from ESMO 2022
    dose dense adjuvant chemotherapy esmo keynote -522 monarch -3 study
  • Critical Care10m 35s

    Is it time to replace calcium based phosphate binder with non-calcium phosphate binders?

    In this video, Dr. Floege talks about the supportive evidence available and guideline recommendations on the preferred use of non-calcium phosphate binders.
    cac score phosphate binders sevelamer lanthanum sucroferric oxyhydroxide kdigo guideline.
  • Prostate Cancer6m 59s

    Managing Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)

    3 randomized clinical trials (SPRATAN- Apalutamide), (PROSPER -Enzalutamide) & (ARAMIS -Darolutamide) have shown consistent and almost similar benefit in Metastasis Free Survival in nmCRPC
    nmcrpc metastasis free survival spartan prosper & aramis clinical trial
  • Myelodysplastic Syndromes2m 31s

    Duration of treatment does it improve outcomes Hypomethylating agents in MD

    Need to maximise the response to hypomethylating agents: Standard of care for high-risk Myelodysplastic Syndromes is Hypomethylating agents. Average time to response is about 3 months with either Azacytidine or Decitabine.
    duration of treatment hypomethylating agents mds
  • For Pharmacist

    For Pharmacist

    Brightcove Cards Listing

    Webinars

    Webinar Cards Listing

    MedBytes

    MedBytes

    Medbytes Cards Listing
    Hi, can I help?
    Chat SupportX
    Support Team
    Hello, how can I help you today?
    Please select one of the below options.

    Find Information

    Unable to Login or Register

    Want to share feedback